Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/43648
Campo DC | Valor | idioma |
---|---|---|
dc.contributor.author | Rodríguez-Hernández, Juan Lizandro | en_US |
dc.contributor.author | Rodríguez-González, Fayna | en_US |
dc.contributor.author | Riaño-Ruiz, Marta | en_US |
dc.contributor.author | Martínez Quintana, Efrén | en_US |
dc.date.accessioned | 2018-11-21T16:48:00Z | - |
dc.date.available | 2018-11-21T16:48:00Z | - |
dc.date.issued | 2018 | en_US |
dc.identifier.issn | 1747-079X | en_US |
dc.identifier.other | WoS | - |
dc.identifier.uri | http://hdl.handle.net/10553/43648 | - |
dc.description.abstract | Introduction: Hyperuricemia has been associated with cardiovascular risk factors but it remains controversial if uric acid is an independent predictor of cardiac mortality. Methods: A total of 503 CHD patients (457 nonhypoxemic and 46 hypoxemic) and 772 control patients fulfilled inclusion criteria. Demographic, clinical, and analytical data [serum uric acid and 24h urine uric acid levels, N‐terminal pro‐B‐type natriuretic peptide (NT‐pro‐BNP), and C‐reactive‐protein (CRP) concentrations] were studied. Survivals curves to determine cardiac death and arterial thrombosis in CHD patients were also examined. Results: Noncyanotic and cyanotic CHD patients had significant higher serum uric acid concentration (5.2 ± 1.5 vs 4.9 ± 1.3mg/dL, P = .007 and 6.7 ± 2.1 vs 4.9 ± 1.3mg/dL, P < .001, respectively) and gout (1% vs 0%, P = .003 and 4% vs 0%, P < .01, respectively) than the control population. Among CHD patients, hyperuricemic patients were significant older and with overweight, used more diuretics, were more cyanotic and had higher serum creatinine, NT‐pro‐BNP and CRP concentrations than nonhyperuricemic. In the multivariable analysis, the body mass index (BMI) (OR 1.09; 95% CI 1.01–1.18), cyanosis (OR 6.2; 95 CI 1.5–24.6), serum creatinine concentration (OR 49; 95% CI 44–538), and being under diuretic treatment (OR 4.5; 95% CI 1.4–14.5) proved to be risk factors for hyperuricemia in CHD patients. The Kaplan–Meier events free survival curves, during a 5.2 ± 2.7 years follow‐up of up time, showed that hyperuricemic CHD patients had significant higher cardiovascular death (P = .002). However, after applying the Cox regression analysis uric acid levels lost its statistical significance. No significant differences were seen in relation to thrombotic events between CHD patients with and without hyperuricemia. Conclusions: CHD patients, noncyanotic and cyanotic, have higher serum uric acid levels and gout than patients in the general population. BMI, renal insufficiency, cyanosis, and the use of diuretics were risk factor for hyperuricemia among CHD patients. | en_US |
dc.language | eng | en_US |
dc.publisher | 1747-079X | - |
dc.relation.ispartof | Congenital Heart Disease | en_US |
dc.source | Congenital Heart Disease [ISSN 1747-079X], v. 13 (5), p. 655-662, (Septiembre-Octubre 2018) | en_US |
dc.subject | 320501 Cardiología | en_US |
dc.subject.other | Cardiovascular death | en_US |
dc.subject.other | Congenital heart disease | en_US |
dc.subject.other | Hyperuricemia | en_US |
dc.subject.other | Inflammation | en_US |
dc.subject.other | Thrombosis | en_US |
dc.title | Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death. | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1111/chd.12620 | - |
dc.identifier.scopus | 85051106997 | - |
dc.identifier.isi | 000452824600003 | - |
dc.contributor.authorscopusid | 57193055539 | - |
dc.contributor.authorscopusid | 24825586600 | - |
dc.contributor.authorscopusid | 35811047900 | - |
dc.contributor.authorscopusid | 23485891800 | - |
dc.identifier.eissn | 1747-0803 | - |
dc.description.lastpage | 662 | en_US |
dc.identifier.issue | 5 | - |
dc.description.firstpage | 655 | en_US |
dc.relation.volume | 13 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.contributor.daisngid | 1386542 | - |
dc.contributor.daisngid | 648988 | - |
dc.contributor.daisngid | 5971737 | - |
dc.contributor.daisngid | 614797 | - |
dc.description.numberofpages | 8 | en_US |
dc.utils.revision | Sí | en_US |
dc.contributor.wosstandard | WOS:Rodriguez-Hernandez, JL | - |
dc.contributor.wosstandard | WOS:Rodriguez-Gonzalez, F | - |
dc.contributor.wosstandard | WOS:Riano-Ruiz, M | - |
dc.contributor.wosstandard | WOS:Martinez-Quintana, E | - |
dc.date.coverdate | Septiembre 2018 | en_US |
dc.identifier.ulpgc | Sí | es |
dc.description.sjr | 1,036 | |
dc.description.jcr | 2,036 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q3 | |
dc.description.scie | SCIE | |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.fullName | Martínez Quintana, Efrén | - |
Colección: | Artículos |
Citas SCOPUSTM
10
actualizado el 02-mar-2025
Citas de WEB OF SCIENCETM
Citations
8
actualizado el 02-mar-2025
Visitas
120
actualizado el 01-mar-2025
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.